Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    End-to-end drug development, specializing in high-potency softgels and liquids, providing global partners with a competitive advantage.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Zofran ODT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,364Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Alto Neuroscience Secures Patent for ALTO-207 in Depression
    Alto Neuroscience Secures Patent for ALTO-207 in Depression

    14 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260114749833/en/Alto-Neuroscience-Strengthens-Intellectual-Property-Portfolio-with-Issuance-of-New-Method-of-Treatment-Patent-for-ALTO-207-in-Depression

    BUSINESSWIRE
    14 Jan 2026
    Share Share
    Shilpa Medicare Aims For US Approval Of Chemo Nausea Drug
    Shilpa Medicare Aims For US Approval Of Chemo Nausea Drug

    09 Jan 2026

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/shilpa-medicare-aims-for-us-approval-of-chemo-nausea-drug-18815

    INDPHARMAPOST
    09 Jan 2026
    Share Share
    Enforcement Report - Week of January 7, 2026
    Enforcement Report - Week of January 7, 2026

    07 Jan 2026

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-7-2026-42601.pdf

    FDA
    07 Jan 2026
    Share Share
    Enforcement Report - Week of December 24, 2025
    Enforcement Report - Week of December 24, 2025

    24 Dec 2025

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-24-2025-58363.pdf

    FDA
    24 Dec 2025
    Share Share
    Shilpa Medicare Reports Successful Phase 3 Trial For OERIS
    Shilpa Medicare Reports Successful Phase 3 Trial For OERIS

    11 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/shilpa-medicare-announces-positive-phase-3-results-for-oeris--a-novel-once-weekly-ondansetron-extended-release-injection-for-chemotherapy-induced-nausea-and-vomiting-cinv-302610656.html

    PR NEWSWIRE
    11 Nov 2025
    Share Share
    Shilpa Medicare's Dabaspet UnitVI Get GMP Certification from SFDA
    Shilpa Medicare's Dabaspet UnitVI Get GMP Certification from SFDA

    11 Jul 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/drug-approval/shilpa-medicare-unit-vi-facility-at-dabaspet-receives-gmp-certification-from-sfda-17386

    INDPHARMAPOST
    11 Jul 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.